Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has shown a drop of 2.1% or 56,229 shares in the short positions. The bets have increased to 2,614,439 shares on November 13,2015 from 2,670,668 shares on October 30,2015.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases.
What: Shares in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) jumped by 10% earlier today after the company announced after the bell yesterday that it would present updated data from its phase 2b study evaluating blisibimod as a treatment for lupus at an ...
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1 by 3 Wall Street Analysts.
An insider Colin Hislop who is Chief Medical Officer of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) 5.30 +0.14 2.71% unloaded some 5,000 shares of the public company having a value near $26,900 USD based on an avg price of $5.4 per share.